Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 EUR | +6.41% | +21.67% | -21.84% |
Mar. 18 | Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development | MT |
Feb. 22 | Transcript : Biotalys NV, 2023 Earnings Call, Feb 22, 2024 |
Sales 2024 * | 3M 3.25M | Sales 2025 * | 3M 3.25M | Capitalization | 110M 120M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 36.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.8 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.57% |
Latest transcript on Biotalys NV
1 day | +4.96% | ||
1 week | +20.00% | ||
Current month | -1.37% | ||
1 month | -10.22% | ||
3 months | -14.08% | ||
6 months | -28.00% | ||
Current year | -22.91% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin R. Helash
CEO | Chief Executive Officer | 59 | Nov. 30 |
Douglas Minder
DFI | Director of Finance/CFO | - | 20-12-31 |
Carlo Boutton
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 12-12-31 | |
Simon Moroney
CHM | Chairman | 65 | 21-03-31 |
Johan Cardoen
BRD | Director/Board Member | 65 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 3.65 | +6.41% | 125 608 |
24-03-18 | 3.43 | +18.69% | 295,279 |
24-03-15 | 2.89 | +5.86% | 9,681 |
24-03-14 | 2.73 | -7.14% | 46,749 |
24-03-13 | 2.94 | -2.00% | 29,376 |
Real-time Euronext Bruxelles, March 19, 2024 at 07:00 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.91% | 120M | |
+2.42% | 3.03B | |
+22.05% | 939M | |
-6.69% | 347M | |
-1.13% | 265M |